Abstract: Compounds of the formula ##STR1## wherein one of the radicals R.sup.1, R.sup.2 or R.sup.3 denotes a straight-chain alkyl group having 4 to 8 C atoms and two vicinal hydroxyl groups in the .omega.,.omega.-1 or .omega.-1,.omega.-2 positions and the two other radicals represent straight-chain or branched alkyl groups having up to 12 C atoms in the position of R.sup.1 and R.sup.3 and up to 4 C atoms in the position of R.sup.2, the total of C atoms in these two alkyl substituents being a maximum of 14, are prepared by oxidation of the corresponding alkenylxanthines and by alkylation with compounds which introduce the dihydroxyalkyl radical or a precursor thereof. The dihydroxyalkyldialkylxanthines are suitable for the treatment of obstructive respiratory tract diseases.

Abstract: Compounds of the formula ##STR1## wherein one of the radicals R.sup.1, R.sup.2 or R.sup.3 denotes a straight-chain alkyl group having 4 to 8 C atoms and two vicinal hydroxyl groups in the .omega.,.omega.-1 or .omega.-1,.omega.-2 positions and the two other radicals represent straight-chain or branched alkyl groups having up to 12 C atoms in the position of R.sup.1 and R.sup.3 and up to 4 C atoms in the position of R.sup.2, the total of C atoms in these two alkyl substituents being a maximum of 14, are prepared by oxidation of the corresponding alkenylxanthines and by alkylation with compounds which introduce the dihydroxyalkyl radical or a precursor thereof. The dihydroxyalkyldialkylxanthines are suitable for the treatment of obstructive respiratory tract diseases.

Abstract: A compound of general formula ##STR1## wherein X represents a radical selected from the group consisting of one of the formulae ##STR2## in which R.sup.1 represents a radical selected from the group(a) a hydrogen atom,(b) an amino group, when X represents an --OR.sup.1 moiety,(c) an alkyl group having from 1 to 6 carbon atoms(d) an at most binuclear aryl group being unsubstituted or substituted by at most 3 substituents of the group halogen atoms, alkyl, alkoxy, halogenalkyl groups each having up to 4 carbon atoms, cycloalkyl groups having 3 to 6 carbon atoms, nitro and cyano groups; andR.sup.2 and R.sup.

Abstract: Compounds of general formula ##STR1## wherein R.sup.1 represents a member selected from the group consisting of (a) an unsubstituted at most binuclear aryl group having from 6 to 10 carbon atoms, such groups substituted by from 1 to 3 equal or different radicals selected from the group consisting of alkyl, halogenoalkyl, alkoxy, dialkylamino each having up to 4 carbon atoms in the alkyl moiety, halogen phenyl, carboxyl, cyano, nitro and hydroxy groups,(b) a 5- to 6-membered heteroaromatic ring wherein the heteroatom is selected from nitrogen, oxygen and sulfur atoms and such rings anellated to a benzene nucleus;R.sup.2 represents a member selected from the group consisting of hydrogen, alkyl having up to 3 carbon atoms, phenyl, cycloalkyl having up to 6 carbon atoms in the ring and cycloalkyl bearing a hydrocarbon bridging radical having up to 2 carbon atoms;R.sup.3 represents hydrogen, hydroxy or acyloxy;R.sup.4 and R.sup.

Abstract: Pyrano-heterocycles of the formula ##STR1## in which R.sup.1 represent hydrogen or an alkyl radical containing up to 4 carbon atoms; R.sup.2 represents hydrogen or an alkyl, alkoxy or haloalkyl radical each having up to 3 carbon atoms, or halogen; or R.sup.1 and R.sup.2 together form an ethylene or propylene group, and R.sup.3 and R.sup.4, independently of each other, are hydrogen or alkyl or alkoxy radicals each of which groups containing up to 3 carbon atoms, which may be unsubstituted or substituted totally or partially with halogen atoms, halogen or alkoxycarbonyl having up to 3 carbon atoms in the alkyl group and R.sup.5 represents a nitro group or hydrogen, their physiologically tolerated salts, processes for preparing these compounds and medicaments containing these compounds.

Abstract: Compounds of general formula ##STR1## wherein X represents a methine group and Y is an oxygen atom, or X represents a nitrogen atom and Y the group NR.sup.3 in which R.sup.3 represents a radical selected from the group consisting of a hydrogen atom, a methyl, ethyl and hydroxyethyl group; and R.sup.1 and R.sup.2 each represent a radical of the group hydrogen atom, an alkyl and hydroxyalkyl group each containing up to 6 carbon atoms, or an aryl group containing up to 10 carbon atoms; and R.sup.1 and R.sup.

Abstract: Compounds of general formula ##STR1## are disclosed wherein appropriate substituents for R.sup.1, R.sup.2 to R.sup.5, R.sup.6, A, Q, X, and Z are defined for these novel hexahydropyrimidines. Procedures for the preparation of these compounds are also given. Because of the highly effective serotonin antagonistic activity in combination with a strong inhibiting effect on thrombocyte aggregation and good compatibility these compounds are effective in treating migraine. Additionally, the compounds also exhibit an anti-histamine activity, cause an increase in erythrocyte fluidity, a psychotropic activity, a weak bradykinin antagonism and hypotensive effects.

Abstract: A physiologically-acceptable compound of one of the formulae ##STR1## wherein R.sup.1 is a member selected from the group consisting of (a) a 6-membered heteroaromatic ring with up to two ring hetero atoms selected from the group consisting of O, N and S, at most one of which is different from nitrogen, and (b) an alkyl group containing from 1 to 4 carbon atoms and substituted by such a heteroaromatic ring;each of R.sup.2 and R.sup.3 is, independently, a hydrogen atom, alkyl having up to 4 carbon atoms, substituted or unsubstituted aryl or, together with the other of R.sup.2 and R.sup.3, unsubstituted --CH.dbd.CH--CH.dbd.CH-- or --CH.dbd.CH--CH.dbd.CH-- substituted by a member selected from the group consisting of alkyl having up to 4 carbon atoms, alkoxy having up to 4 carbon atoms, haloalkyl having up to 4 carbon atoms, halo and nitro;R.sup.

Abstract: Pharmaceutical preparations having hypolipidemic activity, which contain in addition to a pharmaceutically acceptable carrier an effective amount of an imidazolyl-(2)-carbinol of the general formula I ##STR1## in which R represents hydrogen, lower alkyl, phenyl or benzyl, R.sub.1 and R.sub.2 each represent hydrogen or together the group --CH.dbd.CH--CH.dbd.CH--, R.sub.3 and R.sub.4 represent hydrogen, lower alkyl, phenyl, lower haloalkyl, lower alkylphenyl, lower alkoxyphenyl, lower haloalkoxyphenyl, mono- or dihalophenyl, imidazolyl or benzylimidazolyl or R.sub.3 and R.sub.4 are together fluoryl of the formula ##STR2## or of a physiologically tolerable acid addition salt thereof, and process for preparing them.

Abstract: A compound of one of formulae (I) and (II) (of formula sheet) whereinR.sup.1 represents a radical selected from the group consisting of hydrogen alkyl containing up to 6 carbon atoms and being unsubstituted or substituted by at least one of the groups alkoxy and phenylalkoxy containing up to 4 carbon atoms in the alkoxy moiety; aryl or aralkyl each containing from 1 to 4 carbon atoms in the alkyl moiety and being unsubstituted or substituted by at least one substituent selected from the group consisting of alkyl, alkoxy and haloalkyl containing up to 4 carbon atoms, halogen and nitro; a 5- or 6-membered heteroaromatic ring containing up to 2 hetero atoms chosen from O,N and S, at most one of which is different from nitrogen; an alkyl group containing from 1 to 4 carbon atoms substituted by such a heteroaromatic ring;R.sup.2 and R.sup.

Abstract: Compounds of general formula ##STR1## wherein R.sup.1 represents a radical selected from the group consisting of an alkyl group having from 1 to 6 carbon atoms, an unsubstituted aryl group having 6 carbon atoms, an aryl group having 6 carbon atoms being substituted by at least one radical selected from the group consisting of a chlorine atom, alkyl and alkoxy each having up to 2 carbon atoms; and R.sup.2 represents an alkyl group having from 1 to 6 carbon atoms.

Abstract: Novel 0-(dialkylaminoalkyl)-1-alkyl-5-nitroimidazole-(2)-aldoximes are described as well as their manufacture and use for treating protozoal diseases. The novel compounds correspond to the general formula ##SPC1##In which R.sup.1 stand for a hydrogen atom, a methyl, ethyl or hydroxyethyl group, Z stands for a linear or branched alkylene chain of 2 to 3 carbon atoms, and R.sup.2 and R.sup.3 each stands for an identical or different lower alkyl radical having from 1 to 4 carbon atoms or the group --NR.sup.2 R.sup.3 can be part of a saturated heterocyclic ring which may contain further substituents preferably a methyl group or/and hetero atoms, such as, especially the pyrrolidine, piperidine, morpholine, thiamorpholine, tetrahydro-1,4-thiazine-1,1-dioxide and piperazine ring, and HX can be a non-toxic, physiologically acceptable acid.